Cometriq cabozantinib regulatory update

FDA granted Fast Track designation to Cometriq cabozantinib from Exelixis to treat advanced renal cell carcinoma (RCC) in patients who received 1 prior therapy. The spectrum-selective kinase inhibitor of VEGF receptor 2 ( KDR/Flk-1; VEGFR-2) and c-Met receptor tyrosine kinase is in the Phase III METEOR trial to treat metastatic RCC. Top-line data are expected this quarter. ...